ClinicalTrials.gg
Status unknownNCT02468349IMMACULATEUpdated Mar 29, 2018

IMproving reModeling in Acute myoCardial Infarction Using Live and Asynchronous TElemedicine.

An interventional study of Telemedicine in Left Ventricular Remodeling, Medication Adherence and Acute Coronary Syndrome, sponsored by National University Heart Centre, Singapore. Status unknown at 3 sites in Singapore. Open to participants aged 21 Years to 85 Years. Per ClinicalTrials.gov, last updated 2018-03-29.

Sponsored by National University Heart Centre, Singapore · Not applicable, Interventional, and Health services research

How we know

The sponsor has not verified this record recently (last verified Mar 2018), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
21 Years to 85 Years
Sex
All
01

Study summary

The proposed research aims to compare Left ventricular remodeling outcomes among patients with AMI and elevated NT-pro-B-type natriuretic peptide receiving telemedicine-guided post-MI treatment vs. non-telemedicine guided treatment.

Read the detailed description

Acute Myocardial Infarction (AMI) accounts for more than 6,000 admissions to Singapore hospitals each year. Contemporary treatment, including percutaneous intervention (angioplasty and stenting) and adjunctive drug therapy, has reduced early mortality from AMI.

In many healthcare systems, Hospital scorecards stipulate prescription of appropriate drugs upon discharge after hospitalization for AMI. These drugs include aspirin, a platelet P2Y12 inhibitor, angiotensin converting enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARB), beta-blockers and lipid-lowering drugs. Such quality improvement programs have led to an increase in prescription of these drugs upon discharge. Yet, 2 problems remain pervasive:

  1. dose optimization; how the investigators escalate patients to the most effective drug doses, and
  2. drug adherence; whether patients are taking these drugs regularly.

These 2 problems stem largely from the traditional model of episodic care entailing face-to-face visits between patient and healthcare practitioner. Inadequate dose optimization is most relevant to ACE-I/ARB and beta-blockers as healthcare practitioners necessarily prescribe low doses of these drugs at discharge to avoid excessive lowering of blood pressure soon after an AMI. Yet, these drugs are most effective at preventing adverse ventricular remodeling when patients take them at their maximum tolerated doses. In clinical trials, titrating these ACE-I/ARB and beta-blockers to target doses has required weekly outpatient visits, a model of care that most healthcare systems cannot afford.

The investigators hypothesize that a telemedicine-based system of care will lead to a greater reduction in ventricular remodeling as compared with usual care, by improving dose optimization and adherence to ACE-I/ARB and beta-blockers in patients with recent AMI.

Participants with AMI (n=300) will be recruited during the index hospitalization. A key inclusion criteria is an elevated NT-proBNP measurement during the index hospitalization. Participants will first undergo stratified randomization according to ST-segment classification (STEMI/NSTEMI), thereafter randomized into the Telehealth versus Control group in 1:1 sequential block randomization (blocks of 4 and 6). The telehealth intervention group will have their blood pressure and heart rate monitored twice daily at home for 2 months, with alternating titration between ACE-inhibitors and betablockers weekly during the first 2 months. After 2 months, they will continue on telemedicine consultation for 4 months; coaching on drug adherence, drug side-effects management and monitoring of symptoms. A smartphone-based app developed by PEACH Intellihealth will provide structured health education, medication reminders and real-time text messaging with telehealth professionals.

All participants enrolled will be put on 1 year of dual antiplatelet therapy, have a cardiac MRI done both at baseline and 6-months, and followed up with cardiologist review visit at 1, 6 and 12 months. Major adverse cardiovascular and cerebrovascular events will be assessed during each cardiologist review visit, and beyond 12 months, it will be assessed by either phone calls or online/mailed questionnaires at 18 and 24 months.

Four substudies have been planned: a substudy to assess the impact of telemedicine on readmissions (ALTRA), a substudy to assess the effect of telemedicine on adherence to antiplatelet therapy (TICA), a substudy to assess the cost-effectiveness of telemedicine (CEA) and a substudy to assess the effect of telemedicine on MR-PET measured cardiac work efficiency (CES).

02

Conditions studied

  • Left Ventricular Remodeling
  • Medication Adherence
  • Acute Coronary Syndrome

Keywords

  • Acute Myocardial Infarction
  • Telemedicine
  • Readmissions
03

In context

Ventricular Remodeling

105 studies on the registry are indexed under Ventricular Remodeling; 24 are open to participants now.

This study's planned enrollment of 300 is above the median of 81 across 72 interventional studies indexed under Ventricular Remodeling.

Browse Ventricular Remodeling studies →

Lead sponsor

National University Heart Centre, Singapore is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Clinically diagnosed STEMI or NSTEMI* within the last 7 days at high risk of ventricular remodeling

    • Typical history of ischemic chest pain or angina equivalent symptoms (e.g. acute onset dyspnea)
    • Typical rise or fall of cardiac enzymes with at least one value of cardiac troponin I≥10 ug/L.
    • changes required for diagnosis of STEMI: ≥0.1mV ST segment elevation in two or more contiguous limb leads or precordial leads or presence of Q waves ≥0.02 sec in two or more contiguous limb leads or precordial leads, or new onset left bundle branch block (LBBB), *The definition of STEMI and NSTEMI follows the 3rd universal definition of MI [19]
  2. Pre-discharge NTproBNP ≥300 pg/mL for both STEMI and NSTEMI
  3. Undergone PCI for the index event
  4. Age >21 years and \<85 years

Exclusion criteria

Exclusion criteria

  1. to ticagrelor, aspirin or any
  2. Active pathological bleeding
  3. History of intracranial haemorrhage
  4. Bacterial Infection within 6 weeks preceding the primary angioplasty, , disease (e.g. SLE, rheumatoid arthritis, scleroderma and Grave's disease, etc) or on therapy
  5. Women of , known to be pregnant, breast-feeding, or intend to become pregnant during the study period
  6. within last 2 years
  7. History of significant valvular heart disease (moderate or severe MS, MR, AS, AR, TR)
  8. Planned CABG within the next 6 weeks
  9. Unable to be weaned off inotropes or IABP
  10. Active asthma or any other to beta-blockers
  11. Arrhythmias precluding proper CMR image acquisition, such as atrial fibrillation and frequent atrial or ventricular ectopy of > 1 in 5 intrinsic QRS complexes
  12. Contraindications to cardiac magnetic resonance imaging including claustrophobia, pacemaker or ICD implantation, mechanical valve or other metallic implants
  13. Severe liver impairment due to chronic liver disease e.g. advanced alcoholic liver cirrhosis or primary biliary cirrhosis
  14. Significant renal impairment ( \<50ml min-1), end stage renal failure on renal replacement therapy
  15. Anaemia (\<10 g/dL).
  16. Psychosocial barriers to telemedicine adoption (screening for education level, dementia, substance abuse and other psychological disorders)
  17. Participants who cannot be followed up
  18. Participants not able or willing to consent for study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Telemedicine

    The telehealth group will be remotely monitored and managed on medication adherence, dosage titration, and management of drug side effects, through a combination of feed-forward blood pressure monitoring, app-based education and medication reminders, and remote consultations.

    Other: Telemedicine

  • No intervention
    Standard care

    The standard care group will receive face-to-face consultations at one month, 6 months and 12 months.

Interventions

  • OtherTelemedicine

    Participants enrolled will be randomised 1:1 to either telemedicine arm or standard care arm.

06

What researchers measure

Primary outcomes

  1. Difference in Left Ventricular End-Systolic Volume (ml)

    Difference in Left Ventricular End-Systolic Volume (ml) measured on cardiac magnetic resonance imaging

    Time frame: 6 months

Secondary outcomes

  1. Haemodynamic Stress

    Frequency of participants with reduction in NT-proBNP \<20%

    Time frame: 6 months

  2. Infarct size (grams and % of total LV mass)

    Infarct size (grams and % of total LV mass) measured on cardiac magnetic resonance imaging

    Time frame: 6 months

  3. Adenosine diphosphate-induced platelet reactivity

    Difference in Multiplate ADP test (AU\*min)

    Time frame: 6 months

  4. Hospitalisation & readmission

    Difference in incidence of Death, MI, Stroke, readmission for recurrent ischaemia requiring unplanned revascularization and readmission for heart failure.

    Time frame: 2 years

Other outcomes

  1. Quality of Life

    Difference in QoL outcome measures

    Time frame: 2 years

  2. Medication Adherence

    Difference in medication adherence score and pill count

    Time frame: 12 months

07

Study locations

3 of 3 sites recruiting
  • National Heart Centre Singapore
    Singapore, National Heart Research Institute 169609, Singapore
    Recruiting
    • Derek Hausenloy · Contactd.hausenloy@ucl.ac.uk · +65 65166719
    • Derek Hausenloy · Principal investigator
  • National University Heart Centre Singapore
    Singapore, 119228, Singapore
    Recruiting
    • Sock Cheng Poh · Contactsock_cheng_poh@nuhs.edu.sg · +65 66015951
    • Karen Koh · Contact+65 67726884
    • Mark Chan · Principal investigator
  • Tan Tock Seng Hospital
    Singapore, 308433, Singapore
    Recruiting
    • Tasha Mahadi · Contacttashama@ttsh.com.sg · +65 63578124
    • Hee Hwa Ho · Principal investigator
    • Yeong Shyan Lee · Sub investigator
    • Prabath F Joseph · Sub investigator
08

References and documents

Publications

  • Arnold SV, Spertus JA, Masoudi FA, Daugherty SL, Maddox TM, Li Y, Dodson JA, Chan PS. Beyond medication prescription as performance measures: optimal secondary prevention medication dosing after acute myocardial infarction. J Am Coll Cardiol. 2013 Nov 5;62(19):1791-801. doi: 10.1016/j.jacc.2013.04.102. Epub 2013 Aug 21. Erratum In: J Am Coll Cardiol. 2014 Mar 11;63(9):944. PubMed 23973701 ↗
  • Chan MY, Koh KWL, Poh SC, Marchesseau S, Singh D, Han Y, Ng F, Lim E, Prabath JF, Lee CH, Sim HW, Chen R, Carvalho L, Tan SH, Loh JPY, Tan JWC, Kuwelker K, Amanullah RM, Chin CT, Yip JWL, Lee CY, Gan J, Lo CY, Ho HH, Hausenloy DJ, Tai BC, Richards AM; IMMACULATE Investigators. Remote Postdischarge Treatment of Patients With Acute Myocardial Infarction by Allied Health Care Practitioners vs Standard Care: The IMMACULATE Randomized Clinical Trial. JAMA Cardiol. 2021 Jul 1;6(7):830-835. doi: 10.1001/jamacardio.2020.6721. PubMed 33377898 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2015 (actual). Primary completion is estimated for Dec 2019, 54 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2015
First posted
Jun 10, 2015
StartActual
Jun 2015
Primary completionEst.
Dec 2019
CompletionEst.
Dec 2020
Last update
Mar 29, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02468349
Lead sponsor
National University Heart Centre, Singapore
Responsible party
Mark Chan (A/Prof Mark Chan, National University Heart Centre, Singapore) — Principal investigator
First posted
Jun 10, 2015
Start date
Jun 2015
Primary completion
Dec 2019 (estimated)
Completion
Dec 2020 (estimated)
Last update
Mar 29, 2018

Study contacts

Sock Cheng Poh
Contact
sock_cheng_poh@nuhs.edu.sg
+65 9772 0495
Karen Koh
Contact
karen_wl_koh@nuhs.edu.sg
+65 67728664
Mark Chan
principal investigator · National University Heart Centre, Singapore
A. Mark Richards
study chair · National University Heart Centre, Singapore

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion